[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 1.03% 49.00 112,194 09:00:05
Bid Price Offer Price High Price Low Price Open Price
48.00 50.00 49.00 48.50 48.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.52 5.71 6.65 7.4 43
Last Trade Time Trade Type Trade Size Trade Price Currency
16:08:45 O 1,009 49.144 GBX

Optibiotix Health (OPTI) Latest News

More Optibiotix Health News
Optibiotix Health Investors    Optibiotix Health Takeover Rumours

Optibiotix Health (OPTI) Discussions and Chat

Optibiotix Health Forums and Chat

Date Time Title Posts
26/9/202120:16OptiBiotix - The uncensored thread 58,554
23/9/202118:26OptiBiotix Health PLC - 15,538
20/9/202110:12OptiBiotix - Better Science, Better Health. Better buy some!57,609
04/7/202108:45OptiBiotix Health (Facts NOT Fiction)5,373
01/2/202121:24SentimentalRules AKA idoflykathy77

Add a New Thread

Optibiotix Health (OPTI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Optibiotix Health trades in real-time

Optibiotix Health (OPTI) Top Chat Posts

DateSubject
26/9/2021
09:20
Optibiotix Health Daily Update: Optibiotix Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 48.50p.
Optibiotix Health Plc has a 4 week average price of 48.50p and a 12 week average price of 45.50p.
The 1 year high share price is 67.50p while the 1 year low share price is currently 45.50p.
There are currently 87,940,601 shares in issue and the average daily traded volume is 180,662 shares. The market capitalisation of Optibiotix Health Plc is £43,090,894.49.
22/9/2021
16:51
sentiment riles: colinzeal22 Sep '21 - 09:43 - 58526 of 58528 0 2 0 The trouble with OPTI is that it sells off along with the rest of the market, then when the rest of the market picks back up again, old OPTI remains where it is. Pull your finger out SoH! Give us some news! …. That old chestnut. Forget about market since 2018 with record highs and opti closer to 3 year record lows than highs then
22/9/2021
09:43
colinzeal: The trouble with OPTI is that it sells off along with the rest of the market, then when the rest of the market picks back up again, old OPTI remains where it is. Pull your finger out SoH! Give us some news!
19/9/2021
19:14
kreature: I prefer virtual customers for a virtual business with no plant machinery equipment or profit. Less complicated that way surely. Even better would be virtual shareholders and a virtual share price
30/8/2021
17:37
kreature: Just looking at a different company and wondering.....Can the share price of a company be maintained at an astronomical level purely by ‘gaming the market’, or are genuine punters also required in the mix?
28/8/2021
08:47
sentiment riles: Self/wash trades? That’s a big no no It can happen unintentionally of course .,Example 1. a stock with little liquidity, it can control price and if you have some pal you don’t know, Great way to make money on the derivatives re not profit from share price directly, but control it for profiting elsewhere Or maybe something more simple. Broker running two ‘completely different’ methodologies at different desks, causing totally unknown match trades Indeed, the accidents can happen in many ways to avoid flagging But no point going into them because all pretty much, not legal
05/8/2021
16:34
lord loads of lolly: Those dissing today's RNS should perhaps take a look at the market reaction. Share price up over 5% in a single day. With much more to come I suspect. Sure, the price has taken a hammering these past few years whilst earnings visibility remained poor. But that's beginning to change now. And with it, the share price will rise.
05/8/2021
10:06
manc10: from share price on the lse agree a really good update despite covid clearly delaying some deals. H2 looks really interesting with a number of new contracts in the pipeline and also new products being launched. The US deal mentions industrial scale production so is clearly a biggie. Obviously we all know the obesity crisis facing developed countries and now good gut health is also becoming quite mainstream - only this week channel 4 had a programme focusing on improving gut health. Opti are in such a good position to benefit from both. I also like the update below re LPLDL - statins are of limited use and have side effects, so having a natural alternative without side effects could over time be massive. 1. The publication of a placebo-controlled human study which shows that LPLDL® can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, with no reported side effects. This has been with the editorial board of a peer reviewed journal for a number of months. COVID publications are currently being prioritised by editors but we expect this to be published in H2. Publications on how a product works, its safety and efficacy, are important to pharmaceutical partners who may wish to sell LPLDL® as a drug, or Over the Counter (OTC) in high value hospital, GP, and pharmacy channels.
03/8/2021
00:05
sentiment riles: I hope it is really opti selling now you know If the main dumpers at the moment are the ones that bought opti holdings at sbtx lows, Does that mean opti wait to sell 6p again? And hope for more news 😂
02/8/2021
23:30
manc10: you cant beat investing in opti then buying sbtx because opti created it as my mate would say thank the lord i invested in opti and then bought sbtx which made him s$$t loads and i mean s$$t loads thanks soh 250k to create a 90million pound company deal of the decade
30/7/2021
20:50
manc10: OptiBiotix partners US firm for large scale manufacturing of SweetBiotix products Press Release September 15, 2020 LONDON: OptiBiotix Health, a life sciences business, has entered into an agreement with a US company for the purpose of large scale manufacture and commercialisation of a number of SweetBiotix products, a news release said. The agreement grants the US Company an exclusive worldwide license in return for it bearing the costs relating to product manufacturing, marketing, and all future costs relating to the commercialisation of a number of SweetBiotix products. OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch. Additional similar payments will be due on product launch plus royalties on all future product sales. Enhanced royalty payments will be made to OptiBiotix on sale of SweetBiotix products by the Company to 11 application/innovation partners with whom OptiBiotix has been in long term discussions regarding exploring the use of SweetBiotix products in dairy, cereal and beverage applications. The US Company requires its identity and certain commercial terms of the agreement to remain confidential to protect its commercial launch plans. Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce this agreement for SweetBiotix, a family of products based on the concept of creating a sweet fibre with a low glycaemic index which enhances the microbiome. The agreement allows the US Company to invest in the large scale manufacture and commercialisation of a number of SweetBiotix products in return for upfront, annual and product launch milestone payments, plus royalties on all future product sales. “With concerns over the amount of sugar and lack of fibre in consumer diets creating high levels of diabetes and obesity, this agreement brings closer the prospect of replacing ‘unhealthyR17; sugars with healthy sweet fibres which contain no calories and improving microbiome diversity and the benefits of SweetBiotix technology to a global audience.” OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, and diabetes.
Optibiotix Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 20:13:12